Notably, DD1 combined with KPNB1 inhibitors effectively suppresses gastric cancer cell proliferation and tumor growth by enhancing both genomic and non-genomic activities of Nur77, suggesting KPNB1 as a promising therapeutic target in cancer treatment (Zhang et al., 2024). This evidence concerns the gene NR4A1 and gastric cancer.